Biomedicines-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2021-09-14 1de65763m65(暂无匿称)

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0
偏重的研究方向：miRNAs;cancer;Bioinformatics
经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费

82 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2021-05-02 zhanyu

投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题

82 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-12-10 ms5000001127810224 来自浙江省

审稿速度:1.0
经验分享：pending review已经10天了

28 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-03-06 ms8000000077636074

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：骨科非肿瘤
经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢

45 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-03-02 ms7000002142912750 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：医学
经验分享：很快接受

41 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2022-11-04 ms4000000973281563

pending review 一周还有机会吗？

37 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-11-04 ms3000000019971711 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：脑
经验分享：mjjk

31 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-03-01 908919352 来自重庆

投出了，中了，必来还愿

41 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2023-03-11 ms8000000077636074 来自云南省

审稿速度:1.0
偏重的研究方向：骨科非肿瘤
经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1051079, encodeId=63de10510e92b, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2000.0 偏重的研究方向：miRNAs;cancer;Bioinformatics 经验分享：初审14天,两个审稿人30条意见,要求加数据重新计算,大修给了10天时间,已经修回,正在等待结果. 总体感觉还是比较严格的,并没有有些人说的那么水,文章还是要有创新性. 2000瑞士法郎的版面费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3b201694006, createdName=1de65763m65(暂无匿称), createdTime=Tue Sep 14 12:15:29 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962321, encodeId=c212962321fe, content=投了一篇，从投稿到接收差不多一个月，一投过去就是小修，三个人审稿，只其中一个人提出了问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c01577709, createdName=zhanyu, createdTime=Sun May 02 18:26:32 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174017, encodeId=b5c321e40172b, content=审稿速度:1.0 经验分享：pending review已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdd38463891, createdName=ms5000001127810224, createdTime=Sun Dec 10 12:46:04 CST 2023, time=2023-12-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2118021, encodeId=c83421180219e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：骨科非肿瘤 经验分享：第一次小修后三个审稿人只有两个提出很少的建议，经过第二次小修，上个月15号投稿，目前状态Pengding editor decision，请问各位同门，这种状况大概要持续多久？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Mon Mar 06 23:12:33 CST 2023, time=2023-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117230, encodeId=a95c211e230aa, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学 经验分享：很快接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434e5646774, createdName=ms7000002142912750, createdTime=Thu Mar 02 14:40:52 CST 2023, time=2023-03-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2098427, encodeId=500b209842e27, content=pending review 一周还有机会吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054d5421182, createdName=ms4000000973281563, createdTime=Fri Nov 04 08:29:14 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166704, encodeId=7ca82166e0442, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：脑 经验分享：mjjk , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a7b5612327, createdName=ms3000000019971711, createdTime=Sat Nov 04 21:58:03 CST 2023, time=2023-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117090, encodeId=e40c211e09023, content=投出了，中了，必来还愿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fba12754290, createdName=908919352, createdTime=Wed Mar 01 17:40:38 CST 2023, time=2023-03-01, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2118933, encodeId=e1c2211893396, content=审稿速度:1.0 偏重的研究方向：骨科非肿瘤 经验分享：一篇非肿瘤生信干湿结合，2.15转投该杂志，经过3次小修，3.9号前后共22天接收。感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e56412258, createdName=ms8000000077636074, createdTime=Sat Mar 11 14:56:10 CST 2023, time=2023-03-11, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=889370, encodeId=f4868893e031, content=接收快吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48091694938, createdName=李子园, createdTime=Wed Sep 30 11:08:28 CST 2020, time=2020-09-30, status=1, ipAttribution=)]

2020-09-30 李子园

接收快吧

81 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务